Browse All

Current Filters

CLEAR FILTER x

TITLE

Weight Loss With Atogepant in Participants with Migraine and Overweight or Obesity: Interim Analysis of a Phase 3, Multicenter, Open-label, 156-week Extension Study

Chronic Migraine Progression and Persistence: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Safety, Tolerability, and Efficacy of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Phase 3, Multicenter, 24-week, Open-label Study